



**For Immediate Release
May 26, 2015**

**SUNSHINE BIOPHARMA TO RECEIVE THIS WEEK A SAMPLE FROM THE Adva-27a
MANUFACTURING CURRENTLY UNDERWAY AT LONZA IN SWITZERLAND**

Montreal, Quebec, Canada -- (MARKETWIRED) -- Sunshine Biopharma Inc. (OTCQB: "SBFM"), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced today that Lonza Ltd will ship this week a sample of the Company's Adva-27a anticancer compound for biological testing. Lonza is the Company's cGMP drug manufacturing partner in Switzerland where Adva-27a is currently being manufactured for clinical trials for Pancreatic Cancer and Multidrug Resistant Breast Cancer. Upon receipt of the sample Sunshine will perform a series of standardized cytotoxicity assays and other testing to verify the biological activity of the material and provide feedback to Lonza for the next step in the manufacturing process.

"We are very excited to be this advanced in our Adva-27a drug development program," said Dr. Steve N. Slilaty, President and CEO of Sunshine Biopharma. "We have made significant strides in our anticancer drug development efforts particularly in showing the effectiveness of our Adva-27a against multidrug resistant cancer cells, the area that poses the biggest challenge in cancer therapy today."

About Lonza

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life. Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens. Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 9,800 employees worldwide. The company generated sales of about CHF 3.64 billion in 2014 and is organized into two market-focused segments: Pharma & Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.

About Adva-27a

Adva-27a is Sunshine Biopharma's lead anticancer compound, a Topoisomerase II inhibitor, small molecule that has recently been shown to be effective at killing Multidrug Resistant Breast

Cancer cells, Small-Cell Lung Cancer cells, Uterine Sarcoma cells and Pancreatic Cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935. The Company is planning a Phase I clinical trial of Adva-27a for Pancreatic Cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant Breast Cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information:

Sunshine Biopharma Media Contacts:

Renmark Financial Communications Inc.

Robert Thaemlitz: rthaemlitz@renmarkfinancial.com

John Boidman: jboidman@renmarkfinancial.com

Tel.: (416) 644-2020 or (514) 939-3989

www.renmarkfinancial.com

Sunshine Biopharma Inc. Contacts:

Camille Sebaaly, CFO

Tel.: 514-814-0464

camille.sebaaly@sunshinebiopharma.com

Lonza Media Contacts:

Colleen Floreck, +1 201 316 9290, colleen.floreck@lonza.com

Constance Ward, +41 61 316 8840, constance.ward@lonza.com